Literature DB >> 18443641

Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.

Laxmaiah Manchikanti1, Angelie Singh.   

Abstract

Therapeutic opioid use and abuse coupled with the nonmedical use of other psychotherapeutic drugs has shown an explosive growth in recent years and has been a topic of great concern and controversy. Americans, constituting only 4.6% of the world's population, have been consuming 80% of the global opioid supply, and 99% of the global hydrocodone supply, as well as two-thirds of the world's illegal drugs. With the increasing therapeutic use of opioids, the supply and retail sales of opioids are mirrored by increasing abuse in patients receiving opioids, nonmedical use of other psychotherapeutic drugs (in this article the category of psychotherapeutics includes pain relievers, tranquilizers, stimulants, and sedatives, but does not include over-the-counter drugs), emergency department visits for prescription controlled drugs, exploding costs, increasing incidence of side effects, and unintentional deaths. However, all these ills of illicit drug use and opioid use, abuse, and non-medical use do not stop with adults. It has been shown that 80% of America's high school students, or 11 million teens, and 44% of middle school students, or 5 million teens, have personally witnessed, on the grounds of their schools, illegal drug use, illegal drug dealing, illegal drug possession, and other activities related to drug abuse. The results of the 2006 National Survey on Drug Use and Health showed that 7.0 million or 2.8% of all persons aged 12 or older had used prescription type psychotherapeutic drugs nonmedically in the past month, 16.387 million, or 6.6% of the population, had used in the past year, and 20.3%, or almost 49.8 million, had used prescription psychotherapeutic drugs nonmedically during their lifetime. Sadly, the initiates of psychotherapeutic drugs used for nonmedical purposes were highest for opioids. Therapeutic opioid use has increased substantially, specifically of Schedule II drugs. Apart from lack of effectiveness (except for short-term, acute pain) there are multiple adverse consequences including hormonal and immune system effects, abuse and addiction, tolerance, and hyperalgesia. Patients on long-term opioid use have been shown to increase the overall cost of healthcare, disability, rates of surgery, and late opioid use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443641

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  160 in total

1.  Birth-cohort trends in lifetime and past-year prescription opioid-use disorder resulting from nonmedical use: results from two national surveys.

Authors:  Silvia S Martins; Katherine M Keyes; Carla L Storr; Hong Zhu; Richard A Grucza
Journal:  J Stud Alcohol Drugs       Date:  2010-07       Impact factor: 2.582

2.  Patterns of prescription opioid abuse and comorbidity in an aging treatment population.

Authors:  Theodore J Cicero; Hilary L Surratt; Steven Kurtz; M S Ellis; James A Inciardi
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  Prevalence of chronic non-cancer pain in a UK prison environment.

Authors:  Michael Croft; Rachel Mayhew
Journal:  Br J Pain       Date:  2015-05

4.  Opioid prescribing in the UK: can we avert a public health disaster?

Authors:  Cathy Stannard
Journal:  Br J Pain       Date:  2012-02

5.  Guideline-concordant management of opioid therapy among human immunodeficiency virus (HIV)-infected and uninfected veterans.

Authors:  Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Daniel F Weisberg; Amy C Justice; David A Fiellin
Journal:  J Pain       Date:  2014-08-23       Impact factor: 5.820

6.  Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.

Authors:  D Max Crowley; Damon E Jones; Donna L Coffman; Mark T Greenberg
Journal:  Prev Med       Date:  2014-02-09       Impact factor: 4.018

7.  Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.

Authors:  Sindhuri Maddineni; Sunil Kumar Battu; Joe Morott; Majumdar Soumyajit; Michael A Repka
Journal:  J Pharm Pharmacol       Date:  2013-08-20       Impact factor: 3.765

8.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

9.  Development and Feasibility of an Academic Detailing Intervention to Improve Prescription Drug Monitoring Program Use Among Physicians.

Authors:  Kelly S Barth; Sarah Ball; Rachel S Adams; Ruslan Nikitin; Nikki R Wooten; Zaina P Qureshi; Mary J Larson
Journal:  J Contin Educ Health Prof       Date:  2017       Impact factor: 1.355

10.  Opioid Prescriptions for Acute and Chronic Pain Management Among Medicaid Beneficiaries.

Authors:  Chandrashekar Janakiram; Paul Fontelo; Vojtech Huser; Natalia I Chalmers; Gabriela Lopez Mitnik; Avery R Brow; Timothy J Iafolla; Bruce A Dye
Journal:  Am J Prev Med       Date:  2019-08-01       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.